LPA1/3 overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction

Sci Adv. 2019 Oct 9;5(10):eaax2011. doi: 10.1126/sciadv.aax2011. eCollection 2019 Oct.

Abstract

Posthemorrhagic hydrocephalus (PHH) in premature infants is a common neurological disorder treated with invasive neurosurgical interventions. Patients with PHH lack effective therapeutic interventions and suffer chronic comorbidities. Here, we report a murine lysophosphatidic acid (LPA)-induced postnatal PHH model that maps neurodevelopmentally to premature infants, a clinically accessible high-risk population, and demonstrates ventriculomegaly with increased intracranial pressure. Administration of LPA, a blood-borne signaling lipid, acutely disrupted the ependymal cells that generate CSF flow, which was followed by cell death, phagocytosis, and ventricular surface denudation. This mechanism is distinct from a previously reported fetal model that induces PHH through developmental alterations. Analyses of LPA receptor-null mice identified LPA1 and LPA3 as key mediators of PHH. Pharmacological blockade of LPA1 prevented PHH in LPA-injected animals, supporting the medical tractability of LPA receptor antagonists in preventing PHH and negative CNS sequelae in premature infants.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Animals, Newborn
  • Apoptosis
  • Brain / metabolism
  • Brain / pathology
  • Calcium-Binding Proteins / metabolism
  • Disease Models, Animal
  • Ependyma / cytology
  • Ependyma / metabolism
  • Ependymoglial Cells / cytology
  • Ependymoglial Cells / metabolism
  • Infant, Premature, Diseases / chemically induced
  • Infant, Premature, Diseases / pathology*
  • Infant, Premature, Diseases / prevention & control
  • Isoxazoles / pharmacology
  • Isoxazoles / therapeutic use
  • Lysophospholipids / toxicity
  • Macrophages / cytology
  • Macrophages / immunology
  • Macrophages / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Microfilament Proteins / metabolism
  • Phagocytosis
  • Propionates / pharmacology
  • Propionates / therapeutic use
  • Receptors, Lysophosphatidic Acid / antagonists & inhibitors
  • Receptors, Lysophosphatidic Acid / genetics
  • Receptors, Lysophosphatidic Acid / metabolism*

Substances

  • 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid
  • Aif1 protein, mouse
  • Calcium-Binding Proteins
  • Isoxazoles
  • Lysophospholipids
  • Microfilament Proteins
  • Propionates
  • Receptors, Lysophosphatidic Acid
  • lysophosphatidic acid